Piceatannol 3'-O-glucoside
Based on 2 publication(s) in Google Scholar
Piceatannol 3'-O-glucoside, an active component of Rhubarb, activates endothelial nitric oxide (NO) synthase through inhibition of arginase activity with IC50s of 11.22 μM and 11.06 μM against arginase I and arginase II, respectively.
For research use only. We do not sell to patients.
- Purity: 99.65%
- CAS No.: 94356-26-0
- Formula: C20H22O9
- Molecular Weight:406.38
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
HY-101979
Numidargistat
-
HY-15775
Arginase inhibitor 1
-
HY-19548A
BEC hydrochloride
-
HY-112885B
nor-NOHA monoacetate
-
HY-W062216
2-Aminoimidazole
-
HY-W010510
DL-Norvaline
-
HY-N2237R
Piceatannol 3'-O-glucoside (Standard)
-
HY-101979R
Numidargistat (Standard)
-
HY-Y0399
L-Norvaline
-
HY-112885A
nor-NOHA acetate
-
HY-W062216R
2-Aminoimidazole (Standard)
-
HY-W010510R
DL-Norvaline (Standard)
Publications Citing Use of MedChemExpress (MCE) Piceatannol 3'-O-glucoside
More
Biological Activity
NO synthase[1]
IC50: 11.22 μM (Arginase I), 11.06 μM (Arginase II)[1]
Piceatannol 3'-O-glucoside (Piceatannol-3'-O-β-D-glucopyranoside; PG) is a potent component of stilbenes, inhibits the activity of arginase I and II prepared from mouse liver and kidney lysates, respectively, in a dose-dependent manner. In human umbilical vein endothelial cells, incubation of Piceatannol 3'-O-glucoside markedly blocks arginase activity and increases nitrite and nitrate (NOx) production, as measured by Griess assay. In liver lysates, incubation of different concentrations of Piceatannol 3'-O-glucoside significantly decreases arginase I activity (75±5% at 1 μM, 72±7% at 3 μM, 62±1% at 10 μM) compared to untreated control (100±9%). In kidney lysates, the residual arginase activities after incubation of 1, 3 and 10 μM Piceatannol 3'-O-glucoside are 75±6, 74±5, and 53±8%, respectively. Arginase activity is measured in the presence of different concentration of Piceatannol 3'-O-glucoside (from 0 to 120 μM) using liver lysate and kidney lysate. The 50% inhibitory concentrations (IC50) are 11.22 μM for the liver lysate and 11.06 μM for kidney lysate. The values are obtained using the software of Graphpad prizm 4.0. Piceatannol 3'-O-glucoside inhibits arginase activity and increases NO production in HUVECs. Piceatannol 3'-O-glucoside inhibits lipoxygenase activity upto 66% at the concentration of 100 μM and IC50 value is 69 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 94356-26-0
-
Appearance Solid
-
Molecular Weight 406.38
-
Formula C20H22O9
-
Color White to off-white
-
SMILES
O[C@H]([C@H]([C@@H]([C@@H](CO)O1)O)O)[C@@H]1OC2=CC(/C=C/C3=CC(O)=CC(O)=C3)=CC=C2O
-
Synonyms
Quzhaqigan
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Redox Biol
Piceatannol-3'-O-β-d-glucopyranoside mitigates myocardial ischemia-reperfusion injury by inhibiting ferroptosis through the regulation of NDUFS1 lactylation via metabolic reprogramming. [Abstract]2026 Jul:94:104198. PMID: 42134300 -
Redox Biol
Gaylussacin, a stilbene glycoside, inhibits chronic obstructive pulmonary disease in mice. [Abstract]2025 Sep:85:103744. PMID: 40614364
Solvent & Solubility
DMSO : 50 mg/mL (123.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.15 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.15 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Tissue lysates are prepared using lysis buffer (50 mM Tris-HCl, pH 7.5, 0.1 mM EDTA and protease inhibitors) by homogenization at 4°C followed by centrifugation for 20 min at 14,000× g at 4°C. The supernatants are used to assay for arginase activity. The livers or kidneys from C57BL/6 mice (10 weeks) are homogenized in the buffer (50 mM Tris-HCl, 150 mM NaCl, 1% Nonidet P-40, 1 mM EDTA, 1 µg/mL of leupeptin, 1 µg/mL of pepstatin, 1 µg/mL of aprotinin, 1 mM phenylmethylsulfonylflouride, 1 mM sodium orthovanadate, and 1 mM NaF) and centrifuged for 30 min at 14,000× g. The protein amount of the supernatant is analyzed by the Bradford method. Protein (100 µg) are separated in a 10% SDS-PAGE and then transferred to a nitrocellulose membrane. The blots are incubated with a monoclonal anti-arginase I, anti-arginase II, anti-endothelial nitric oxide synthase (eNOS), or anti-β-tubulin antibodies followed by the secondary antibody. The signals are detected using an enhanced chemiluminescence detection reagent with X-ray films[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[2]
Twenty 10-week-old male wild-type (WT) (C57BL/6J) and ApoE-/- mice are studied. To determine the effect of Piceatannol 3'-O-glucoside on vascular reactivity, aortic rings isolated from 20 male C57BL/6J WT mice fed a normal diet (ND) and 20 male ApoE-/- mice fed an HCD are studied for 6 weeks. Aortic rings are incubated with or without Piceatannol 3'-O-glucoside (50 μM) for 18 h. For the pathological assay, Piceatannol 3'-O-glucoside is administered in the drinking water to ApoE-/- mice for 6 weeks when the mice are started on the HCD. Given that each mouse consumes ~10 mL water/day this represents a daily dose of ~500 μg/mouse/day of Piceatannol 3'-O-glucoside[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Woo A, et al. Piceatannol-3'-O-beta-D-glucopyranoside as an active component of rhubarb activates endothelial nitric oxide synthase through inhibition of arginase activity. Exp Mol Med. 2010 Jul 31;42(7):524-32. [Content Brief]
[2]. Woo A, et al. Arginase inhibition by piceatannol-3'-O-β-D-glucopyranoside improves endothelial dysfunctionvia activation of endothelial nitric oxide synthase in ApoE-null mice fed a high-cholesterol diet. Int J Mol Med. 2013 Apr;31(4):803-10. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4608 mL | 12.3038 mL | 24.6075 mL | 61.5188 mL |
| 5 mM | 0.4922 mL | 2.4608 mL | 4.9215 mL | 12.3038 mL | |
| 10 mM | 0.2461 mL | 1.2304 mL | 2.4608 mL | 6.1519 mL | |
| 15 mM | 0.1641 mL | 0.8203 mL | 1.6405 mL | 4.1013 mL | |
| 20 mM | 0.1230 mL | 0.6152 mL | 1.2304 mL | 3.0759 mL | |
| 25 mM | 0.0984 mL | 0.4922 mL | 0.9843 mL | 2.4608 mL | |
| 30 mM | 0.0820 mL | 0.4101 mL | 0.8203 mL | 2.0506 mL | |
| 40 mM | 0.0615 mL | 0.3076 mL | 0.6152 mL | 1.5380 mL | |
| 50 mM | 0.0492 mL | 0.2461 mL | 0.4922 mL | 1.2304 mL | |
| 60 mM | 0.0410 mL | 0.2051 mL | 0.4101 mL | 1.0253 mL | |
| 80 mM | 0.0308 mL | 0.1538 mL | 0.3076 mL | 0.7690 mL | |
| 100 mM | 0.0246 mL | 0.1230 mL | 0.2461 mL | 0.6152 mL |
Piceatannol 3'-O-glucoside Related Classifications
HY-N2237 Related Classifications
Powered by Bioz